Atrium Therapeutics, Inc. (RNA)
7.84
-0.30
(-3.69%)
USD |
NASDAQ |
Oct 02, 16:00
7.98
+0.14
(+1.79%)
Pre-Market: 20:00
Atrium Therapeutics Shareholders Equity (Quarterly) : 214.58M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 214.58M |
| March 31, 2026 | 234.10M |
| December 31, 2025 | -62.71M |
| Date | Value |
|---|---|
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | -61.11M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Tenax Therapeutics, Inc. | 113.59M |
| Exicure, Inc. | 0.977M |
| Century Therapeutics, Inc. | 232.34M |
| Absci Corp. | 246.13M |
| Celularity, Inc. | -35.26M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 280.51M |
| Total Liabilities (Quarterly) | 65.94M |
| Debt to Equity Ratio | 0.0078 |
| Current Ratio | 8.730 |
| Net Debt Paydown Yield | 0.44% |